Document is current
Any future updates will be listed below
-
Authors
Chaudhuri, Nazia https://orcid.org/0000-0003-3325-6996
Azuma, Arata
Sroka-Saidi, Kamila
Erhardt, Elvira
Ritter, Ivana
Harari, Sergio
-
Funding
Funding for this research was provided by:
The clinical trials and pharmacovigilance programme described in this paper were supported by Boehringer Ingelheim.
- License Information
-
More Information
Article History
Received: 31 July 2024
Accepted: 3 October 2024
First Online: 28 October 2024
Declarations
:
: Nazia Chaudhuri reports consulting fees from Boehringer Ingelheim, Redx, Liminal BioSciences, Vicore Pharma AB, Bridge Biotherapeutics, tranScrip and speaker fees from Boehringer Ingelheim. Nazia Chaudhuri is an Editorial Board member of <i>Advances in Therapy</i>. Nazia Chaudhuri was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions Arata Azuma reports research support from Boehringer Ingelheim; consulting fees from Boehringer Ingelheim and Kyorin Pharma Co.; speaker fees from Boehringer Ingelheim and participation on a data safety monitoring board for Taiho Co. and Toray Co. Kamila Sroka-Saidi, Elvira Erhardt and Ivana Ritter are employees of Boehringer Ingelheim. Sergio Harari reports research support from Aerovate, AstraZeneca, and Boehringer Ingelheim and consulting fees from Roche.
: This analysis did not require institutional review board (IRB) approval as it was based on aggregate patient de-identified data from a pharmacovigilance database.
